The new immunosuppressive era

Annali Italiani di Chirurgia

Volumn 70, Issue 1, 1999, Pages 1-19

  Lo Monte, A I ^b   Ciancio, G ^a,c   Burke, G ^a   Roth, D ^a   Miller, J ^a  

^a JACKSON MEMORIAL HOSPITAL   (United States)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Bone marrow; Chimerism; Immunosuppressive agents; Organ transplantation; Rejection; Tolerance

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

BONE MARROW TRANSPLANTATION; CHIMERA; GRAFT REJECTION; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; ORGAN TRANSPLANTATION; REVIEW;

BONE MARROW TRANSPLANTATION; CHIMERA; GRAFT REJECTION; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY;

EID: 0032612669     PISSN: 2239253X     EISSN: 2239253X     Source Type: Journal    
DOI: None     Document Type: Article

References (201)

1. Borel J.F., Feurer C., Gubler H.U., Stahelin H.: Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions, 6:468-475, 1976.
2. Calne R.Y., White D.J, Thiru S. et al: Cyclosporin A in patients receving renal allografts from cadaver donors. Lancet, 2:1323-1327, 1978.
3. Starzl T.E., Todo S., Fung J., Demetris A.J., Venkataramman R., Jain A.: FK506 for liver, kidney, and pancreas transplantation. Lancet, 2:1000-1004, 1989.
4. Allison A.C., Almquist S.J., Muller C.D., Eugui E.M.: In vitro immunosuppressive effects of mycophenolic acid and ester pro-drug, RS-61443. Transplant Proc, 23:10-14, 1991.
5. Sollinger H.W., Deierhoi M.H., Belzer F.O., Diethelm A.G., Kauffman R.S.: RS 61443 a phase I clinical trial and pilot rescue study. Transplantation, 53:428-432, 1992.
6. Kino T., Hatanaka H., Miyata S. et al.: FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-S06 in vitro. J Antibiot, 40:1256-1265, 1987.
7. Ho S., Clipstone N., Timmermann L. et al.: The mechanism of action of Cyclopsorin A and FK506. Clin Immunol and Immunopath, 80:S40-S45, 1996.
8. Sawada S., Suzuki G.E.N., Kawase Y., Takaku F.: Novel immunosuppressive agent, FK506: in vitro effects on cloned T cell activation. J Immunol, 139:1797-1803, 1987.
9. Tzakis A., Webb M., Nery J., et al.: Experience with intestinal transplantation at the University of Miami. Transplant Proc, 28:2748-2749, 1996.
10. Burke G.W., Alejandro R., Ciancio G. et al.: The use of FK506 in simultaneous pancreas/kidney transplantation: Rescue, induction, and maintenance immunosuppression. Transplant Proc, 27:3123-3124, 1995.
11. Ciancio G., Burke G., Roth D., Miller J.: Use of intravenous FK506 to treat acute rejection in simultaneous pancreas-kidney transplant recipients on maintenance oral FK506. Transplantation, 63:785-788, 1997.
12. Gruessner R.W.G., for the tacrolimus pancreas transplant study group: Tacrolimus in pancreas transplantation a multicenter analysis. Clin Transplantation, 11:299-312, 1997.
13. Pham S.M., Kormos R.L., Hattler B.G. et al.: A prospective trial of tacrolimus (FK506) in clinical heart transplantation: intermediate-term results. J Thorac Cardiovas Surg, 111:764-772, 1996.
14. Keenan R.J., Konishi H., Kawai A. et al.: Clinical trial of tacrolimus versus cyclosporine in transplantation. Ann Thorac Surg, 60 580-58, 1995.
15. Przepiorka D., Ippoliti I., Woo M. et al.: Tacrolimus and mini-dose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood, 88:4383-4389, 1996.
16. Herget S., Heemann U., Friedrich J., Kribben A., Wagner K., Philipp TH.: Initial experience with tacrolimus rescue therapy in OKT3 resistant rejection. Clin Nephrol, 45:352-354, 1996.
17. Eberkard O., Kliem V., Oldhafer K. et al.: How best to use tacrolimus (FK506) for treatment of steroid and OKT3 -resistant rejection after renal transplantation. Transplantation, 61:1345-1349, 1996.
18. Jordan M.L., Shapiro R., Naraghi R. et al.: Tacrolimus rescue therapy for renal transplant rejection. Transplant Pro, 28 2119-2120, 1996.
19. Ciancio G., Roth D., Burke, G. et al.: Renal transplantation in a new immunosuppressiveera. Transplant Proc, 27:812-813, 1995.
20. Woodle E.S., Thistlethwaite R., Gordon J.H. et al.: A multi-center trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. Transplantation, 62:594-599, 1996.
21. Pirsh J.D., Miller J., Deierhoi M.H., Vicenti F., Filo R.: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation, 63:977-983, 1997.
22. Ciancio G., Rosen A., Loreto-Grand B. et al.: The current advantage of FK506 in cadaver kidney transplantation. Transplant Proc, 28:1000-1001, 1996.
23. Roth D., Colona J., Burke G. et al.: Primary therapy with FK506 (FK) in kidney transplantation. Proceedings of the American Society of Transplant Physicians, 15th Annual Scientific Meeting 1996; [abstract] 264: 150.
24. Vicenti F., Laskow D.A., Neylan J.F., Mendez R., Matas A.J.: One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. multicenter FK506 kidney transplant group. Transplantation, 61:1576-1581, 1996.
25. Jensik S.C., for the FK506 Kidney Transplant Study Group: Programs and Abstracts of the International Congress on Immunosuppression, December 1997, Orlando, FL; (Abstract) #123.
26. Sollinger H.W., Knechtle S.J., Reed A. et al.: Experience with 100 consecutive simultaneous kidney-pancreas transplants with bladder drainage. Ann Surg, 214:703-711, 1991.
27. Harilharan S., Munda R., Cavallo T. et al.: Rescue therapy with tacrolimus after combined kidney/pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity. Transplantation, 61:1161-1165, 1996.
28. Stratta R.J., Taylor R.J., Castaldo P. et al.: FK506 induction and rescue therapy in pancreas transplant recipients. Transplant Proc, 28:991-992, 1996.
29. Alloway R.R., Russell W.C., Gaber L.W. et al.: Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: The Memphis experience. Transplant Proc, 28:995-997, 1996.
30. Gruessner R.W.G., Burke G., Stratta R. et al.: A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. Transplantation, 61:261-273, 1996.
31. Xenos E.S., Ciancio G., Burke G.W. et al.: The use of tacrolimus as induction and maintenance immunosuppression in renal cadaveric transplant recipients over the age of 60. Clin Transplantation, 11:497-499, 1997.
32. Ciancio G., Siquijor A.P., Burke G.W. et al.: Post-transplant Iymphoproliferative disease in kidney transplant patients in the new immunosuppressiveera. Clinical Transplantation, 11:243-249, 1997.
33. Penn I.: Cancers complicating organ transplantation. New Engl J Med, 23:1767-1769, 1990.
34. Tanabe K., Koga S., Takahashi K et. al.: Diabetes mellitus after renal transplantation under FK506 (tacrolimus) as primary immunosuppression. Transplant Proc, 28:1304-1305, 1996.
35. Groth C.G., Ohlman S., Gannedahl G., Ericzon B.G.: New immunosuppressive drugs in transplantation. Transplant Proc, 25:2681-2683.i, 1993.
36. Deierhoi M.H., Kauffman R.S., Hudson S.L. et al.: Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center. Ann Surg, 217:476-484, 1993.
37. Sollinger H.W., Belzer F.O., Deierhoi M.H. et ai.: RS-61443 (Mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection. Ann Surg, 216:513-519, 1992.
38. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.: A blinded randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation, 61:10-1037, 1996.
39. Sollinger H.S., for the US Renal Transplant Mycophenolate Mofetil Study Group.: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation, 60:225-232, 1995.
40. Garcia-Morales R., Carreno M., Mathew J. et al.: The effects of chimeric cells following donor bone marrow infusions as detected by PCR-Flow assays in kidney transplant recipients. J Clin Invest, 99:1118-1129, 1997.
41. Roth D., CoIona J., Burke G.W. et al.: Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. Transplantation, 65:248-252, 1998.
42. Mendez R., for the FK506 MMF Dose-Ranging Kidney Transplant Study Group.: FK506 and mycophenolate mofetil in renal transplant recipients: Six-months results of a multicenter, randomized dose ranging trial. Transplant Proc, 30:1287-1289, 1998.
43. Shapiro R., Jordan M.L., Scantlebury V.P. et al.: A prospective, randomized trial of Tacrolimus/Prednisone versus Tacrolimus/Prednisone/ Mycophenolate Mofetil in cadaveric renal transplantation-first report. Program and Abstracts of the 16th Annual Scientific Meeting of the American Society of Transplant Physicians, Chicago, IL:May, 1997; (Abstract)#293
44. Zucker K., Rosen A., Tsaroucha A. et al.: Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant recipients receiving tacrolimus and mycopheolate mofetil in combination therapy, and analogous in vitro findings. Transplant Immunol, 5:225-232, 1997.
45. Klupp J., Bechstein W.O., Platz K.P. et al.: Mycophenolate mofetil added to immunosuppression after liver transplantation: First results. Transplant Int, 10:223-228, 1997.
46. Klintmalm G.B., Asher N.L., Busuttil R.W. et al.: RS-61443 for treatment-resistant human liver rejection. Transplant Proc, 25:697, 1993.
47. Gavlik A., Goldberg M.G., Tsarouchan A. et al.: Mycophenolate mofetil rescue therapy in liver transplant recipients. Transplant Proc, 29:549-552, 1997.
48. Freise C.E., Herbet M., Osorio R.W. et al.: Maintenance immunosuppression with prednisone and RS-61443 alone following liver transplantation. Transplant Proc, 25:1758-1759, 1993.
49. McDiarmid S.V.: Mycophenolate mofetil in liver transplantation. Clin Transplantation, 10:140-145, 1996.
50. Blum A., Aravot D.: Heart Transplantation. An update. Clin Cardiol, 19:930-938, 1996.
51. Kobashigawa J.A., Laks H., Drinkwater D.C. et al.: The University of California at Los Angeles experience in heart transplantation. In Clinical Transplants, 1995. Edited by Terasaki PI. Los Angeles: UCLA Tissue Typing Laboratory; 10:129-135, 1995.
52. Taylor D.O., Ensley R.D., Olsen S.L., Dunn D., Renlund D.G.: Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experince in heart transplantation. J Heart Lung Transplant, 13:571-582, 1994.
53. Renlund D.G., Gopinathan S.K., Kfoury A.G., Taylor D.O.: Mycophenolate mofetil (MMF) in heart transplantation: rejection, prevention and treatment. Clin Transplant, 10(1, Pt 2):136-139, 1996.
54. Kobashigawa J.A., Renlund D.G., Olsen S.L. et al.: Initial results of RS-61443 for refractory cardiac rejection. J Am Coll Cardiol, 19:203A (Abstract), 1992.
55. Kirklin J.K., Bourge R.C., Nattel D.C. et al.: Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): Initial clinical experience. J Heart Lung Transplant, 13:444-450, 1995.
56. Costanzo M.R. on behalf of the Mycophenolate Mofetil Study Investigators.: Results of the randomized trial mycophenolate mofetil vs azathioprine in heart transplantation. Program and Abstracts of the 16th Annual Scientific Meeting of The American Society of Transplant Physicians Chicago, IL: May, 1997; (Abstract)#9.
57. Meiser B.M., Jagaiello-Kraatz M., Pfeiffer M. et al.: The efficacy of mycophenolate mofetil treatment after heart transplantation is highly dependent on mycophenolate trough levels. Circulation 1997; 96(Suppl)347 (Abstract).
58. Weppler D., Khan R., Frangulidis G.P. et al.: Status of liver and gastrointestinal transplantation at the University of Miami. In Clinical Transplants. 1996. Edited by Terasaki PI. Los Angeles: UCLA Tissue Typing Laboratory; 14:187-201, 1996.
59. Karatzas T., Khan F., Tzakis A.G.: Clinical intestinal transplantation: Experience in Miami. Transplant Proc, 29:1787-1789, 1997.
60. Regazzi M.B., Alessiani M., Reggiani P. et al.: Pharmacokinetics of FK506 and mycophenolic acid in experimental and clinical intestinal transplantation. Transplant Proc, 29:1857-1860, 1997.
61. lacona I., Alessiani M., Spada M., Regazzi M.B.: Mycophenolic acid in combination with FK506: A pharmacokinetic study in piglets after small-bowel transplantation. Transplant Proc, 29:701-702, 1997.
62. Alessiani M., Spada M., Costa A. et al.: Morphological and functional changes in small-bowel allografts of pigs under combined tacrolimus and mycophenolate mofetil immunosuppression. Transplant Proc, 29:691-692, 1997.
63. Tzakis A.G., Nery J.R., Thompson A. et al.: New immunosuppression regimens in clinical intestinal transplantation. Transplant Proc, 29:683-685, 1997.
64. Stratta R.J. et al.: Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipients: a multicenter report: The FK/MMF Multi-Center Study Group. Transplant Proc, 29:654-655, 1997.
65. Burke G.W., Ciancio G., Garcia-Morales R. et al.: Evidence for microchimerism in peripheral blood, bone marrow and skin following donor bone marrow/kidney-pancreas transplantation at 3 years. Transplant Proc, 30:1555, 1998.
66. Burke G.W., Ricordi C., Karatzas T. et al.: Donor bone marrow infusion in simultaneous pancreas/kidney transplantation with OKT3 induction: Evidence for augmentation of chimerism. Transplant Proc, 29: 1207-1208, 1997.
67. Burke G.W., Ciancio G., Alejandro R. et al.: Use of tacrolimus and mycophenolate mofetil for pancreas-kidney transplantation with or without OKT3 induction. Transplant Proc, 30:1544-1545, 1998.
68. Ciancio G., Burke G., Levi D. et al.: Simultaneous pancreas/kidney transplantation without antibody therapy induction. J Urol, 709A:159, 1998.
69. Ciancio G., Burke G., Viciana A. et al.: Use of intravenous tacrolimus to reverse vascular rejection in kidney and simultaneous kidney-pancreas transplantation. Transplant Proc, 30:1536-1537, 1998.
70. Garcia-Morales R., Esquenazi V., Zucker K. et al.: Assessment of the effects of cadaveric donor bone marrow on chimerism kidney transplant recipients by the polymerase chain reaction-flow technique. Transplant Proc, 29:1219-1221, 1997.
71. Garcia-Morales R., Esquenazi V., Carreno M. et al.: PCR-flow analysis used to detect the levels of chimerism in peripheral blood of bone-marrow infused organ allograft recipients at the time of rejection episodes. Transplant Proc, 29:2179-2180, 1997.
72. Ciancio G., Carreno M., Mathew J. et al.: Human donor bone marrow cells can enhance hyporeactivity in renal transplantation using maintenance FK506 and OKT3 induction therapy. Transplant Proc, 28:943-944, 1996.
73. Garcia-Morales R., Carreno M., Mathew J. et al.: Continuing observations on the regulatory effects of donorspecific bone marrow cell infusions and chimerism in kidney transplant recipients. Transplantation, 65:956-965, 1998.
74. Ciancio G., Garcia-Morales R., Burke G.W. et al.: Donor bone marrow, chimerism, histocompatibility and renal allograft rejection. Transplant Proc, (In press).
75. Garcia-Morales R., Esquenazi V., Zucker K. et al.: An assessment of the effects of adaver donor bone marrow on kidney allograft recipient blood cell chimerism by a novel technique combining PCR and flow cytometry. Transplantation, 62:1149-1160, 1996.
76. Zheng X.F., Schreiber S.L.: Target of rapamycin proteins and their kinase activities are required for meiosis. Pro Nati Acad Sci, 94:3070-3075, 1997.
77. Hausen B., Morris R.: Review of immunosuppression for lung transplantation. Novel drugs, new uses for conventional immunosuppressants, and alternative strategies. Clin Chest Med, 18 353-366, 1997.
78. Belham C.M., Scott P.H., Twomey D.T. et al.: Evidence that thrombin-stirnulated DNA synthesis in pulmonary arterial fibroblast involves phosphatidylinositol 3-kinase-dependent p70 ribosomal S6 kinase activation. Cell Signal, 9:109-116, 1997.
79. Wilson M.A., Burt A.R., Milligan G., Anderson N.G.: Mitogenic signalling by g opiod receptors expressed in rat-J fibroblast involves activation of the p70, M/p896k s6 kinase. Biochem J, 3254:217-222, 1997.
80. Javier A.F., Bata-Csorgo Z., Ellius C. et al.: Rapamycin (Sirolimus) inhibits proliferation cell nuclear antigen expression and blocks cell cycle in the G, Phase in human keratocyte stem cells. J Clin Invest, 99:2094-2099, 1997.
81. Mohacsi P.J., Tuller D., Hulliger D., Wijngaard P.L.J.: Different inhibitory effects of immunosuppressive drugs on human and rats aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant, 16:484-492, 1997.
82. Goggins W.C., Fisher R.A., Dattilo E.B. et al.: Analysis of functional renal allograft tolerance with single-dose rapamycin based induction immunosuppression. Transplantation, 63:310-314, 1997.
83. Poon M., Marx S.O., Gallo R. et al.: Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest, 98:2277-2283, 1996.
84. Schmid C., Heemann U., Azuma H., Tilney N.L.: Rapamycin inhibits transplant vascubpathy in long-surviving rat heart allografts. Transplantation, 60:729-733, 1995.
85. Gregory C.R., Huang X., Pratt R.E., et al.: Treatment with rapamycin and mycophenolic acid reduces arterial intimai thickening produced by mechanical injury and allows endothelial replacement. Transplantation, 59:655-661, 1995.
86. Sehmid C., Heemann, Tilney N.L.: Factors contributing to the development of chronic rejection in heterotopic rat heart transplantation. Transplantation, 64:222-228, 1997.
87. Fahrini J.A., Berry G.J., Morris R.E., Rosen G.D.: Rapamycin inhibits development of obliterative airway disease in a murine heterotopic airway disease in a murine heterotopic airway transplant model. Transplantation, 63:533-537, 1997.
88. Reichenspurner H., Soni V., Nitschke M. et al.: Obliterative airway disease after heterotopic tracheal xenotransplantation. Transplantation, 64:373-383, 1997.
89. Sehgal S.N., Camardo J.S., Scarola J.A., Maida B.T.: Rapamycin (sirolimus, rapamune). Curr Opin Nephrol Hyperten, 4:482-487, 1995.
90. Murgia M.G., Jordan S., Kahan B.D.: The side effect profile of sirolimus: A phase I study in quiescent cyclosporine prednisone treated renal transplant recipient. Kidney Int, 49: 209-216, 1996.
91. Pescovitz M.D., Kahan B.D., Julian B., Neylan J., Chan G.: Sirolimus (SRL) permits early steroid withdrawal from triple therapy renal propkylaxis regimen. Program and Abstracts of the 16th Annual Scientific Meeting of The American Society of Transplant Physicians, Chicago, IL: May, 1997; (Abstract) #708.
92. Schuurman H.J., Cottens S., Fuchs S. et al.: SDZ, a new rapamycin derivative. Transplantation, 64:32-35, 1997.
93. Schuler W., Sedrani R., Cottens S. et al.: SDZ. a new rapamycin derivative; Pharmacological properties in vitro and in vivo. Transplantation, 64:36-42, 1997.
94. Morris R.E.: Mechanisms of action of new immunosuppressive drugs. Kidney Inter, 49 (Suppl 53):26-38, 1996.
95. Groth C.G., Ohlman S., Gannedahl G. et al.: New immuno-suppressise drugs in transplantation. Transplant Proc, 25:2681-2683, 1993.
96. Anemiya H and Japanese Collaborative Transplant Study Group of NKT-01: Immunosuppressive mechanism and action of deoxyspergualin in experimental and clinical studies. Transplant Proc, 27:31-32, 1995.
97. Matas A.J., Gores P.F., Kelley S.L. et al.: Pilot evaluation of 15-deoxyspergualin for refractory acute renal transplant rejection. Clin Transplant, 8:116-119, 1994.
98. Halloran P.F.: Immunosuppressive agents in clinical trials in transplantation. Am J Med Sci, 313:283-288, 1997.
99. Oka T., Yoshimura N.: Immunosuppression in organ transplantation. Jap J Pharmacol, 71:89-100, 1996.
100. Shoker A.S.: Immunopharmacologic therapy in renal transplantation. Pharmacotherapy, 16:562-575, 1996.
101. Katoh H., Ohkohchi N., Orii T., Doi H., Satomi S.: Effectiveness of 15-Deoxyspergualin on steroid-resistant acute rejection in living related liver transplantation. Transplant Proc, 29:533-534, 1997.
102. First M.R.: An update on new immunosuppressive drugs undergoing preclinical trials: Potential applications in organ transplantation. Am J Kidney Dis, 29:303-317, 1997.
103. Turka L.A., Dayton J., Sinclair G., Thompson C.B., Mitchell B.S.: Guanine ribonucleo depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine. J Clin Invest, 87:940-948, 1991.
104. Ogawa N., Koyama I., Shibata T. et al.: Suppressive effects of combination therapy with mizoribine and FK506 on the development of accelerated coronary artery disease and myocardial rejection after heart transplantation. Transplant Proc, 28:1394-1396, 1996.
105. Kokado Y., Ishibahi M., Jiang H., Takahara S., Sonoda T.: Low-dose cyclosporin, mizoribine and prednisolone in renal transplantation: A new triple-drug therapy. Clin Transplant, 4:191-197, 1990.
106. Mita K., Akiyama N., Nagao T., Sugimoto H. et al.: Advantages of mizoribine over azathioprine combination therapy with cyclosporine for renal transplantation. Transplant Proc, 22:1679-1681, 1990.
107. Lee H.A., Slapak M., Ven Katraman G. et al.: Mizoribine as an alternative to azathioprine in triple-therapy immunosuppressant regimens in cadaver renal transplantation. Transplant Proc, 25:2699-2700, 1993.
108. Sonda K., Takahashi Tanabe K. et al.: Clinical pharmacokinetic study of mizoribine in renal transplantation patients. Transplant Proc, 28:3643-3648, 1996.
109. Lee H.A., Slapak M., Venkatraman G. et al.: Mizoribine as an alternative to azathioprine in triple therapy immunosuppressive regimens in cadaveric renal transplantation: Two successive studies. Transplant Proc, 27:1050-1051, 1995.
110. Silva H.T., Morris R.E.: Leflunomide and malononitrilamides. Am J Med Sci, 313:289-301, 1997.
111. Xu X., Blinder L., Shen J. et al.: In vivo mechanism by which leflunomide controls Iymphoproliferative and autoimmune disease in MRL/Mpj-Ipr mice. J Immunol, 159:167-174, 1997.
112. Elder R.T., Xu X., Williams J.W., et al.: The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cell through two biochemical mechanisms. J Immunol, 159:22-27, 1997.
113. Silva H.T., Cao W., Shorthouse R.A., Loffler M., Morris R.E. In vitro and in vivo effects of leflunomide, brequinar, and cyclosporine on pyrimidine biosynthesis. Transplant Proc, 29:1292-1293, 1997.
114. Mladenovic V., Domljan Z., Rozman B. et al.: Safet and effectiveness of leflunomide in the treatment of patients with active rheu-matoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum, 38:1595-15603, 1995.
115. Barlett R.R., Brendel S., Zielinski T., Schorlemmer H.V.: Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis. Transplant Proc, 3074-3078, 1996.
116. Wennberg L., Groth C.G., Tibell A. et al.: Triple treatment with cyclosporine, leflunomide and mycophenolate prevents rejection of pig islets transplanted into rats and primates. Transplant Proc, 29:2498, 1997.
117. Wennberg L., Karlsson-Parra A., Sundberg B et al.: Efficacy of immunosuppressive drung in islet xenotransplantation: Leflunomide in combination with cyclosporine and mycophenolate mofetil prevents islet xenograft rejection in the pig-to-rat model. Transplantation, 63:1234-1242, 1997.
118. Mital D., Guao Z., Chong A.S.F. et al.: Successfid xenotransplantation of adult porcine islets in NOD and BALB/c mice with leflunomide and cyclosporine. Transplant Proc, 29:2166-2167, 1997.
119. Guo Z., Chong A.S.F, Shen J. et al.: In vivo effects of leflunomide on normal pancreatic on normal pancreatic islet and syngeneic islet graft function. Transplantation, 63:716-721, 1997.
120. Guo Z., Chong A.S.F., Shen J. et al.: Leflunomide, a potential immunosuppressant for pancreatic islet transplantation. Transplant Proc, 29:1296-1207, 1997.
121. Guo Z., Chong A.S.F., Shen J. et al.: Prolongation of rat islet allograft survival by the immunosuppressive agent leflunomide. Transplantation, 63:711-716, 1997.
122. Ratcliffe P.J., Dudley C.R.K., Higgins R.M. et al.: Randomized controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet, 348:643-648, 1996.
123. Hollander A.A.M.J., Hene R.J., Hermans H.J., Van Es L.A., Van Der Woude F.J.: Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: A randomized study. J Am Soc Nephrol, 8:294-301, 1997.
124. Cronin II D.C., Bruce D.S., Newell K.A. et al.: Tacrolimus therapy for retractor renal allogratt rejection. Experience with steroid withdrawal. Transplant Proc, 29:307, 1997.
125. Stegall M.D., Everson G.T., Schroter G. et al.: Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss. Hepatology, 25:173-177, 1997.
126. Mazariegos G.V., Reyes J., Marino I.R. et al.: Weaning of immunosuppression in liver transplant recipients. Transplantation, 63:243-249, 1997.
127. Shapiro R., Jordan M.L., Scantlebury W.P. et al.: The outcome after steroid withdrawal in renal transplant patients receiving tacro-limus-based immunosuppression. Programs and Abstracts of the International Congress on Immunosuppression December 1997, Orlando, FL; (Abstract) #55.
128. Metchnikof F.E.: Ann Inst Pasteur, 13:737, 1899.
129. Waksman B.H., Arbonys S., Amason B.G.: J Exp Med, 14:997, 1961.
130. Grant G., Monaco A.P., Wood M.L., Russel B.S.: Studies on heterologous anti-lymphocyte from normal II. Effects on the immune response. J Immunol, 96:229-238, 1966.
131. rd Annual Scientific Meeting of The American Society of Transplant Surgeons, Chicago, IL: May, 1997; (Abstract) #6.
132. Cosimi A.B., Colvin R.B., Burton R.C. et al.: Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment inrecipients of renal allografts. N Engl J Med, 305:308-314, 1981.
133. Cosimi A.B., Burton R.C., Colvin R.B. et al.: Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation, 32:535-539, 1981.
134. Queen C., Schneider W.P., Selick H.E. et al.: A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA, 86:10029-10033, 1989.
135. Cole M.S., Anasetti C., Tso J.Y.: AHuman Igb2 variants of chimeric anti-CD3 are non-mitogenic to T cells. J Immunol, 159:3613-3621, 1997.
136. Theze J., Alzari P.M., Bertoglio J.: Interlcukin-2 and its receptors: recent advances and new immunological functions. Immunol Today, 58:419-486, 1996.
137. Hesse C.J., van Gelder T., Vaessen L.M., et al.: Pharmacodynamics of prophylactic antirejection therapy with an anti-interleukin-2 receptor monoclonal antibody (BT563) after heart and kidney transplantation. Immunopharmacology, 30:237-246, 1995.
138. Kirkman R.L., Shapiro M.E., Carpenter C.B., McKay D.B., Milford E.L., Ramos E.L., Tilney N.L., Waldmann T.A., Zimmerman C.E., Strom T.B.: A randomized prospective trial of anti-Tac monocolnal antibody in human renal transplantation. Transplantation, 51:107-113, 1991.
139. Vincenti F., Lantz M., Birnbaum J. et al.: A phase I trial of humanized anti-interlcukin 2 receptor antibody in renal transplantation. Transplantation, 63:33-38, 1997.
140. Langrehr J.M., Nussler N.C., Neuman U. et al.: A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation. Transplantation, 63:1772-1781, 1997.
141. Vicenti F., for the Bi-Continental triple therapy HAT study group.: A phase III multicenter study of humanized anti-Tac (HAT) for the prevention of rejection in primary cadaveric renal allograft recipients. Program and Abstracts of the 16th Annual Scientific Meeting of The American Society of Transplant Physicians Chicago, IL: May, 1997; (Abstract) #702.
142. Kahan B.D., Rajagopalan P.R., Hall M.L. et al., on behalf of the US Simulect Study group: Reduction of acute cellular rejection in renal allograft patients with Basiliximab (Simuloct™). Program and Abstracts of the 16th Annual Scientific Meeting of The American Society of Transplant Physicians Chicago, IL: May, 1997;(Abstract)#704.
143. Nashan B., Moore R., Schmidt A.G. et al., on behalf of the CHIB 201 International Study Group: Reduction of acute rejection by Basiliximab (Simulect™), in renal allograft recipients. Program and Abstracts of the 16th Annual Scientific Meeting of The American Society of Transplant Physicians Chicago, IL: May, 1997; (Abstract) #705.
144. Carls S., Wiesel M., Daniel V. et al.: Rescue therapy with inter-leukin-2 receptor antibody in high risk kidney transplant patients: a 3-year follow-up study. Transplant Proc, 29:320-332, 1997.
145. Saitovitch D., Bushell A., Mabbs D.W., Morris P.J., Wood K.J.: Kinetics of induction of transplantation tolerance with nondeple-ting anti-Cd4 monoclonal antibody and donor-specific transfusion before transplantation: a critical period of time is required before the development of immunological tolerance. Transplantation, 61:1642-1647, 1996.
146. Arima, Lehmann M., Wayne Flye M.: Induction of donor specific transplantation tolerance to cardiac allografts following treatment with nondepleting (RIB 5/2) or depleting (OX-38) anti-CD4 mAb plus intrathyrnic or intravenous donor alloantigen. Transplantation, 63:284-292, 1997.
147. Tak P.P., van der Lubbe P.A., Cauli A. et al.: Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum, 38:1457-1465, 1995.
148. Moreland L.W., Pratt P.W., Bucy R.P. et al.: Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody: long-term followup of CD4 + T cell counts. Arthritis Rheum, 37:834-838, 1994.
149. Yin D.P., Sankary H.S., Chong A.S.F. et al.: Effect of anti-CD4 monoclonal antibody combined with human CTLA4Ig on the survival of hamster liver and heart xenografts in lewis rats. Transplantation, 64:317-321, 1997.
150. Kuttler B., Rosing K., Hahn H.J.: Anti-CD4/CyA therapy causes prevention of autoimmune but not allogeneic destruction of grafted islets in BB rats. Transplant Proc, 29:2163-2165, 1997.
151. Risch K., Becker G., Graser E. et al.: Inhibition of chronic rejection after kidney transplantation by ani-CD4 treatment. Transplant Proc, 29:328-329, 1997.
152. Cooperative Clinical Trials in Transplantation Research Group: Murine OKT4A immunosuppression in cadaver donor renal allograft recipients. Transplantation, 63:1087-1095, 1997.
153. Cooperative Clinical Trials in Transplantation Research Group: Murine OKT4A immunosuppression in cadaver donor renal allograft recipients. Transplantation, 63:1243-1251, 1997.
154. Kirk A.D., Harlan D.M., Armstrong N.N. et al.: CTLA4-Ig and anti-CD40 ligand prevent allograft rejection in primates. Proc Natl Acad Sci, 94:8789-8794, 1997.
155. Larsen C.P., Elwood E.T., Alexander D.Z. et al.: Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature, 381:434-438, 1996.
156. Markees T.G., Phillips N.E., Noelle R.J. et al: Prolonged survival of mouse skin allografts in recipients treated with donor sple-nocytes and antibody to CD40 ligand. Transplantation, 64:329-335, 1997.
157. Subbotin V.M., Sun H., Aitouche A. et al.: Reversal of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and anti-CD40L monoclonal antibody. Program and Abstracts of the 16th Annual Scientific Meeting of The American Society of Transplant Physicians Chicago, IL: May, 1997;(Abstract)#692.
158. Ghobrial R.M., Busuttil R.W., Kupiec-Weglinski W.: Monoclonal antibodies. Curr Opin Organ Transplantation, 2:82-88, 1997.
159. Lazarovits A.I., Poppema S., Zhang Z. et al.: Prevention and reversal of renal allogratt rejection by antibody against CD45RB. Nature, 380:717-720, 1996.
160. Auersvald L.A., Rothstein D.M., Oliveira S.C. et al.: Indefinite islet allograft survival in mice after a short course of treatment with anti-CD45 monoclonal antibodies. Transplantation, 63:1355-1369, 1997.
161. Auersvald L.A., Rothstein D.M., Oliveira S.C., Khuong C.Q., Basadonna G.P.: Anti-CD45RB treatment prolongs islet allograft survival in mice. Transplant Proc, 29:771, 1997.
162. Le Mauff B., Le Meur Y., Hourmant M. et al.: A dose-searching trial of anti-LFAl monoclonal antibody in first kidney transplant recipients. Kidney Int, 1996, 49(Suppl 53):44-50.
163. Hourmant M., Bedrossian J., Durand D. et al.: A randomized multicenter trial comparing leukocyte function-associated antigen-1 with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. Transplantation, 62:1565-1570, 1996.
164. Xu X.Y., Honjo K., Devore-Carter D., Bucy R.P.: Immunosuppression by inhibition of cellular adhesion mediated by leukocyte function-associated antigen-1/intercellular addesion molecule-1 in murine cardiac. Transplantation, 63:876-885, 1997.
165. Korom S., Meester I.D., Stadbauer T.H.W. et al.: Inhibition of CD26/Dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation, 63:1495-1500, 1997.
166. Davies J.D., Cobbold S.P., Waldmann H.: Strain variation in susceptibility to monoclonal antibody-induced transplantation tolerance. Transplantation, 63:1570-1573, 1997.
167. Judge T.A., Tang A., Spain L.M. et al.: The in vivo mechanism of action of CTLA4Ig. J Immunol, 156:2294-2299, 1996.
168. Pearson T.C., Alexander D.Z., Corbascio M. et al.: Analysis of the B7 costimulatory pathway in allograft rejection. Transplantation, 63:1463-1469, 1997.
169. Azuma H., Chandraker A., Nadeu K. et al.: Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. Immunol, 93:1239-1244, 1996.
170. Lakkis F.G., Konieczny B.T., Saleem S. et al.: Blocking the CD28-B7 T cell costimulation pathway induces long-term cardiac allograft acceptance in the absence of IL-4. J Immunol, 158:2443-2448, 1997.
171. Pearson T.C., Alexander D.Z., Hendrix R. et al.: CTLA4-lg plus bone marrow induces long term allograft survival and donor-specific unresponsiveness in the murine model. Transplantation, 61:997-1004, 1996.
172. Yin D.P., Sankary H.N., Williams J., Krieger N., Fathman C.G.: Induction of tolerance to small bowel allografts in higher-respon-der rats by combining anti-CD4 with CTLA4Ig. Transplantation, 62:1537-1539, 1996.
173. Guéreke B., Gingras M., Wood K., Roy R., Tremblay J.P.: Immunosuppression with monoclonal antibodies and CTLA4 Ig after myoblast transplantation in mice. Transplantatioy, 62:962-967, 1996.
174. Hale D.A., Gottschalk R., Maki T., Monaco A.P.: Use of CTIA4-Ig in combination with conventional immunosuppressive agents to prolong allograft survival. Transplantation, 64:897-900, 1997.
175. Kechtle S.D., Vargo J., Fechner Y., Zhai M.J., Hanaway F., Scharff H., Hu D.M. et al.: FN-18CRM9 immunotoxin given peri-transplant with donor bone marrow indeces operational tolerance to kidney allograft. Transplantation, 63:1-6, 1997.
176. Thomas J.M., Neville D.M., Contreras J.L., Eckhoff D.E., Meng G., Lobashevsky A.L., Wang P.X., Huang Z.Q., Verbanac K.M., Haisch C.E., Thomas F.T.: Preclinical studies of allograft tolerance in rhesus monkeys: a novel anti-CD3-immunotoxin given peri-transplant with donor bone marrow induces operational tolerance to kidney allografts. Transplantation, 64:124-135, 1997.
177. Bach T.H.: Inhibition of endothelial cell function: Should this be a main goal of immunosuppressive strategies. J Heart Lung Transplant, 16:493-495, 1997.
178. Sayegh M.H., Krensky A.M.: Novel immunotherapeutic strategies using MHC derived peptides. Kidney Int, 49(Suppl 53): 13-20, 1996.
179. Iyengar A.R., Bonham C.A., Antonysamy M.A. et al.: Striking augmentation of hematopoietic cell chimerism in noncytoablated allogeneic bone marrow recipients by FLT3 ligand and tacrolimus. Transplantation, 63:1193-1199, 1997.
180. Monaco A.P., Wood M.L., Maki T., Gozzo J.J., DeFazio S.: The use of donor-specific antigen for the induction of immunologic unresponsiveness to experimental and clinical allograft. Transplant Proc, 20(1):122-130, 1988.
181. Monaco A.P., Wood M.L., Maki T., Hartner W., De Fazio S., Gozzo J.J.: Cyclosporine and unresponsiveness to allografts induced by polyclonal antilvmphocvte serum and donor-specific bone marrow. Transplant Proc, 20(3):36-48, 1988.
182. Barber W.H., Mankin J.A., Laskow D.A. et al.: Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation, 51:70-75, 1991.
183. Fontes P., Rao A.S., Demetris A.J. et al.: Bone marrow augmentation of donor-cell chimerism in kidney, liver heart, and pancreas islet transplantation. Lancet, 344:151-155, 1994.
184. Shapiro R., Rao A.S., Fontes P. et al.: Combined kidney/bone marrow transplantation-evidence of augmentation of chimerism. Transplantation, 59:306-309, 1995.
185. Thomas J.M., Verbanac K.M., Smith J.P., et al.: The facilitating effect of one-DR sharing in renal allograft tolerance induced by donor bone marrow in rhesus monkeys. Transplantation, 59:245-255, 1995.
186. Wren S.M., Nalesnik M., Hronakes M.L., Oh E., Ildstad, S.T.: Mixed chimerism to induce tolerance for solid organ transplantation. J Ped Surg, 26:439-443, 1991.
187. Rappaport F.T., Bachvaroff R.J., Watanabe K. et al.: Immunologic tolerance: Irradiation and bone marrow induction of canine allogeneic unresponsiveness. Transplant Proc, 9:891-894, 1977.
188. Ildstad S.T., Sachs D.H.: Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allograft or xenogeneic. Nature, 307:168-170, 1984.
189. Kimikawa M., Sachs D.H., Colvin R.B., Bartholomew A, Kawai T., Cosimi A.B.: Modifications of the conditioning mixed chimerism and donor-specific tolerance in cynomolgus monkeys. Transplantation, 64:709-716, 1997.
190. Kawai T., Cosimi A.B., Colvin R.B. et al.: Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkey. Transplantation, 59:256-262, 1997.
191. Charlton B., Auchincloss H., Fathman C.G.: Mechanisms of transplantation tolerance. Ann Rev Immunol, 12:707-734, 1994.
192. Sachs D.H.: CCETS basic science lecture. Transplantation tolerance. Ann Thorac Surg, 56:1221-1227, 1993.
193. Aradhye S., Turka L.A.: Will tolerance become a clinical reality? Km J Med Scy, 313:310-314, 1997.
194. Lechler R., Bluestone J.A.: Transplantation tolerance-putting the pieces together. Curr Opin Immunol, 9:631-633, 1997.
195. Starai T.E., Demetris A.J., Murase N, et al.: The lost chord: microchimerism and allograft survival. Immunol Today, 17:577-584, 1996.
196. Billingham, Brent L., and Medawar P.B.: Actively acquired tolerance of foreign cells. Nature, 172:603-606, 1953.
197. Wood K, Sachs D.H.: Chimerism and transplantation tolerance: Cause and effect. Immunol Today, 17:584-587, 1996.
198. Rao A.s., Fontes P., Iyengar A. et al.: Augmentation of chimerism with perioperative donor bone marrow infusion in organ transplant recipients: 44 months follow-up. Transplant Proc, 29:1184-1885, 1997.
199. Ricordi C, Karatzas T, Nery J, et al.: High-dose donor bone marrow infusions to enhance allograft survival. Transplantation,; 63:7-11, 1997.
200. Ierino F.L., Banerjee P.T., Gere J. et al.: A genetic approach toward tolerance induction in a pig to baboon preclinical xenotransplantation model. Program and Abstracts of the 16th Annual Scientific Meeting of The American Society of Transplant Physicians Chicago, IL: May, 1997; (Abstract) #631.
201. Mayfield R.S., Hayashi H., Sawada T. et al.: The mechanism of specific prolongation of class 1-mismatched skin grafts induced by retroviral gene therapy. Eur J Immunol, 27:1177-1181, 1997.